crc-22-0489_fig2.png (737.67 kB)

FIGURE 2 from Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer

figure

posted on 2023-08-30, 14:20 authored by Matjaz Rokavec, Elif Özcan, Jens Neumann, Heiko Hermeking

Performance of the 61-gene signature in predicting RFS in training cohorts. A, KM analysis of RFS according to the 61-gene signature classifier in the pooled training dataset. B, ROC graph showing the sensitivity, specificity and AUC value of the 61-gene signature to predict relapse in the pooled training dataset. The red dot indicates the recurrence score threshold that was used to determine sensitivity and specificity. C, Risk of recurrence as a continuous function of the 61-gene signature recurrence score within 10 years after surgery in the pooled training dataset. The shaded area around the curve represents the lower and upper 95% confidence interval (CI). D–I, KM analysis of RFS according to the 61-gene signature classifier in the indicated training datasets.

Funding

Deutschen Konsortium für Translationale Krebsforschung (DKTK)

History

ARTICLE ABSTRACT

We identified and validated a 15-gene expression signature for robust prognostication and stratification of patients with stage II colorectal cancer, with superior performance when compared with currently used biomarkers. Therefore, the 15-gene expression signature has the potential to improve the prognostication and treatment decisions for patients with stage II colorectal cancer.